DSM-Firmenich DSFIR.AS
DSM-Firmenich is a Swiss specialty chemicals company that produces fragrances, flavors, nutritional ingredients, and health solutions, selling to consumer goods manufacturers and pharmaceutical companies. DSM-Firmenich shows acceptable financial health (score 5.67) but with a net debt/EBITDA of 3.40 and a low operating margin (7.93%). Quality is weak (ROIC 2.97%, ROE 1.87%) and valuation is demanding (P/E 70.39), with very negative earnings growth (-56.20%). Momentum is strong (35.37%), but fundamentals do not support it.
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
DSM-Firmenich is a Swiss specialty chemicals company that produces fragrances, flavors, nutritional ingredients, and health solutions, selling to consumer goods manufacturers and pharmaceutical companies. DSM-Firmenich shows acceptable financial health (score 5.67) but with a net debt/EBITDA of 3.40 and a low operating margin (7.93%). Quality is weak (ROIC 2.97%, ROE 1.87%) and valuation is demanding (P/E 70.39), with very negative earnings growth (-56.20%). Momentum is strong (35.37%), but fundamentals do not support it.
Score by category
| Category | Score |
|---|---|
| Financial health | 5.4 |
| Quality / Moat | 2.5 |
| Valuation | 2.2 |
| Growth | 2.2 |
| Dividend | 2.1 |
| Momentum | 7.7 |
| Risk & Context | 7.7 |
OVERALL SCORE: 3.9/10
Context and risks
Regulatory investigation in India over price collusion in the fragrance sector; risk of fines and reputational damage in a key growth market.
News considered in the analysis
- Exclusive-India investigates fragrance giants over price collusion, document shows — Investigación regulatoria en India por presunta colusión de precios; si se confirma, podría acarrear multas y dañar la reputación en un mercado de crecimiento.
- Fine Fragrance’s Sweet Smell of Success Lasts — Indica demanda resiliente en fragancias finas, un segmento de alto margen para la compañía.
- DSM-Firmenich Medisca Deal Highlights U.S. Vitamin API And Valuation Upside — El acuerdo con Medisca refuerza la presencia en el mercado estadounidense de API vitamínicos, un área con potencial de crecimiento.
- Dividend Investors: Don't Be Too Quick To Buy DSM-Firmenich AG (AMS:DSFIR) For Its Upcoming Dividend — Advierte sobre la sostenibilidad del dividendo dado el alto payout, un riesgo a considerar.
- Assessing DSM-Firmenich (ENXTAM:DSFIR) Valuation After Recent Share Price Swings — Análisis de valoración sin información nueva relevante.
Verdict: Hold; valuation and quality do not justify entry, and positive momentum could reverse if the India investigation or weak fundamentals weigh more.
Main risk: The combination of a net debt/EBITDA of 3.40 and a payout of 178.57% makes the company vulnerable to a rising rate environment and a potential dividend cut.
Other Basic Materials companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →